B2B ad examples

Revisit the key takeaways from our #MSToronto 2026 sessions. #RocheNeurology #MS

Access the latest data and session highlights on MS care now. #MSToronto 2026 #RocheNeurology #MS

Discover how dosing, safety, trial design and patient engagement must adapt for immunotherapy in chronic disease populations.

Chronic disease populations need a different approach to dosing, safety and trial design. Download the whitepaper to explore key strategies.

Picture your life in Australia Thinking about what your next chapter could look like? I-MED Radiology Network is visiting the UK this November to connect with radiologists interested in exploring career opportunities in Australia. From potential locations and working arrangements to registration pathways, we’d love to help you understand your options and what a move could look like for you. Meet us at the @BIR Annual Congress in Birmingham, or join us for dinner in Birmingham or London. 📍 BIR Annual Congress | 12–13 November 🍽️ Birmingham dinner | 12 November, 7pm 🍽️ London dinner | 14 November, 7pm Not attending BIR? You can still join us for dinner or request a virtual conversation. Book your chat here: https://lnkd.in/gVsNJMkK

We talk a lot about "person-centered care" in this sector, but what does it actually look like from a leadership perspective? This week at GreenTree Programs, our team sat down for a roundtable discussion on this exact topic. After years in this field, it is always refreshing to strip back the buzzwords and look at what it really takes to build a person-centered culture. We narrowed it down to three core principles: 1. It starts with how we treat our staff. You cannot expect a frontline worker to deliver deeply empathetic care if leadership treats them like just another file number. Person-centered care is a ripple effect, it starts with supporting your team exceptionally well so they actually have the emotional bandwidth to support others. 2. Policies must serve people, not just compliance. It is so easy for leadership to get bogged down in administrative paperwork. If a policy is just words on paper designed to make our reporting easier, it isn't serving its mission. We have to fiercely protect humanity from red tape. 3. Lead from the floor, not the desk. Decisions made in a boardroom rarely reflect the reality of the living room. I will be the first to admit I can be guilty of getting stuck behind my desk, but leadership must stay connected to the day-to-day moments. We have to walk in the shoes of our frontline staff to truly understand the perspective of the people we serve. I want to put the question out to my network: What does person-centered care look and feel like at your agency or place of work? What do best practices look like for your team? Let me know in the comments! 👇

Take one minute to expand your knowledge of vascular access best practices. This week, we're taking a closer look at the difference between scrubbing the hub and using disinfecting caps, and how disinfecting caps can support consistent connector care and protection between accesses. #VascularAccess #InfectionPrevention #InfusionTherapy #PatientSafety #DualCap

Save up to 62% on gene synthesis, DNA fragments and plasmid DNA and 60% on custom DNA clones. Explore the offers today.

Build your Finance career at GSK Poland as an Order-to-Cash Collection Analyst. Work with North American markets and support key collections processes in an international environment. The role requires flexibility in working patterns, with periodic shifts aligned to US business hours.

Join us on Plasma Proteins Science Day to get the latest insights into the detection, monitoring, and discrimination of systemic amyloidosis.

How can earlier action change the future for patients with IgA Nephropathy (IgAN)? For many living with IgA Nephropathy, diagnosis comes late, often after kidney damage has already occurred. The impact extends beyond long term kidney health, influencing life decisions around work, family and future plans. 📖 The latest insights and KDIGO 2025 guidelines reinforce the urgency of early action to help improve long-term outcomes. ▶️ Watch the video below and visit www.targetproteinuria.com to access expert interviews, educational resources and the latest disease-state information. At CSL, supporting improved care for patients remains at the heart of our mission. #IgAN #Nephrology #LatestIgANInsights #CSL

Imaging is a journey, not a single step. From sites and image collection to quality control, readers and central review, every part of the workflow contributes to the data behind your clinical endpoints. Collective Minds connects the entire imaging journey in one centralized platform. Bring your imaging workflow together and keep your trial moving toward its endpoints.

Multiple trials shouldn’t mean multiple imaging workflows. Collective Minds connects image collections, QC, central review and reader workflows, giving CRO teams a more connected and centralized way to manage imaging in clinical trials. See how it works.

Strong tablets shouldn’t mean slow disintegration. Nutracore LFP helps manufacturers produce durable, low-friability tablets while supporting fast disintegration, smooth compression and easy ejection. Its reliable performance has been designed for today’s nutraceutical formulations.

Our new label-friendly lubricant is designed to simplify nutraceutical tablet and capsule manufacturing. Nutracore LFP supports improved flow, smooth compression, easy ejection and consistent quality—without the need for extra sifting or pre-blending. Discover a simpler way to manufacture nutraceutical tablets and capsules.

Wearables and self-monitoring are shifting care into the home, putting medical devices at the centre of it. Our CCO explains how Atlantia runs the trials behind that shift: full-service design, organisation and execution, in-house recruitment from 40,000+ participants, and full visibility into budgets, recruitment and timelines throughout. We specialise in Class 2 devices, reporting to the FDA and equivalent European bodies.

Join us on November 5, 2026, for the second webinar in our free series: The value of Automation – Practical application insights for smarter labs In this session we'll explore: Automating cell-based assays: from cell viability to potency Ismail Cisse, PhD, Field Support Scientist for High Throughput applications at Promega, will offer a practical look at what changes when cell-based assays move to an automated liquid handler. Using cell viability as a starting point, he'll explore how automation can support more consistent workflows and help reduce manual variability. He'll also look at the role of reproducibility in bioassays for biologics, where dose-response curves and relative potency measurements support release and stability testing. Why attend? • Understand which cell-based assay characteristics are well suited to automation. • Learn what to check when transferring an established manual protocol. • Explore how automation can support more consistent cell seeding, dilution, and reagent addition. • See how automated workflows can help reduce assay variability. • Discover where automation can add value first—from cell viability assays to potency testing. Leave with a clearer view of how to assess, transfer, and automate cell-based workflows with greater confidence 📅 November 5, 2026 | 4:00 p.m. CET Join us live and bring your questions about laboratory automation.

La radiochirurgie franchit une nouvelle étape. Le ZAP-X, installé à l'Hôpital Lariboisière à Paris, permet de traiter des lésions cérébrales sans intervention chirurgicale, avec une précision inédite. Le Dr Nathaniel Scher, oncologue radiothérapeute à l'Institut de Radiothérapie et de Radiochirurgie H.Hartmann, fait partie des équipes qui font vivre cette innovation au quotidien. Dans cette vidéo, il explique le principe de la radiochirurgie : des centaines de microfaisceaux concentrés sur la lésion tumorale, de fortes doses ciblées sur la tumeur, et un cerveau épargné autour. Le patient est allongé, ne ressent rien, et repart le jour même. Derrière la machine, une expertise médicale conjointe : les équipes de l'Institut de Radiothérapie H. Hartmann et de l'AP-HP - oncologues radiothérapeutes, physiciens, neurochirurgiens - travaillent ensemble au service des patients. Un partenariat public-privé que le Dr Scher résume simplement : "Ce qu'on veut, c'est que les patients vivent plus longtemps et surtout qu'ils vivent bien." #Innovation #Radiochirurgie #Oncologie

⚜️ Louis XIV souffrait-il d’une maladie rénale ? Une question que l’Histoire ne permet pas de trancher… mais que la médecine peut aujourd’hui éclairer. Au XVIIᵉ siècle, l’insuffisance rénale n’est pas encore identifiée comme une pathologie et les médecins ne disposent d’aucun des outils diagnostiques dont nous bénéficions aujourd’hui. Pourtant, les archives historiques et les récits laissés par les contemporains du Roi Soleil décrivent certains troubles qui interpellent encore les spécialistes. À partir de ces témoignages, le docteur Stanislas Bataille, néphrologue, et Philippe Charlier, anthropologue, se sont intéressés à l’hypothèse d’une maladie rénale chez Louis XIV. Aujourd’hui, la situation a bien changé. 🩺 Les maladies rénales peuvent être dépistées, diagnostiquées et prises en charge, parfois avant même l’apparition de symptômes. Prendre soin de ses reins, c’est aussi penser au dépistage. En cas de facteur de risque ou de question concernant votre santé rénale, parlez-en à un professionnel de santé. 👉 Pour aller plus loin, retrouvez notre article consacré à l’insuffisance rénale, à son diagnostic, à ses symptômes et à ses traitements : https://lnkd.in/dw5638-d #Recherche #HistoireMédicale #SantéRénale

You've looked at Atlantia. Here's the actual detail: full visibility into your budget, recruitment and timelines, 40,000+ participants in our recruitment database, and a team that runs your trial end to end. Watch the two-minute breakdown.

Aiforia® Breast Cancer Suite improves workflow efficiency and diagnostic accuracy in pathology labs. It consists of AI models and a matching Aiforia® Clinical Suite Viewer that support pathologists in the histological grading of breast cancer and in the assessment of breast cancer IHC markers. Request a demo to learn if it could optimize your current workflow. ⬇️

🫁 Er du lungemediciner eller sundhedsperson med interesse for lungemedicin? Så sæt ✘ i kalenderen fredag d. 9. april 2027. Nye kronikerpakker, sundhedsreformen og fremtidens patientforløb stiller nye krav til det lungemedicinske område. Til Nationalt Lungesymposium 2027 sætter førende danske og internationale eksperter fokus på, hvad det betyder for din kliniske hverdag. 💡 Kom og vær med – vi glæder os til at se dig! 🙌 DK-16795-10-26-R&I

Aiforia® Breast Cancer Suite offers advanced tools for histological grading and biomarker detection, ensuring precision and efficiency. - Aiforia® Breast Cancer Grading - Aiforia® Breast Cancer Ki67 - Aiforia® Breast Cancer ER - Aiforia® Breast Cancer PR - Aiforia® Breast Cancer HER2 - Aiforia® Lymph Node Metastasis Take the next step to see how AI seamlessly integrates to enhance every step, from sample analysis to diagnosis. ⬇️

Does RNA manufacturing really need more assays, or do we need to get more from the ones we already have? That question came through strongly in our latest podcast, with three different perspectives: 🔬 Mark Dickman called for greater standardisation, particularly around how we measure mRNA integrity and dsRNA. Without it, how meaningful are comparisons between methods, labs or suppliers? 🧬 Francis Combes questioned whether adding more QC assays is really the answer. Could we instead combine critical quality attributes and better connect them to biological outcomes? ⚙️ Ashish Dhir took the conversation upstream, arguing that DNA template quality needs more attention as a determinant of the RNA we ultimately produce. These aren’t separate challenges. They point towards a broader shift in RNA manufacturing: from measuring quality at the end of the process to understanding and controlling it throughout. From advanced analytical tools and improved enzymes to next-generation process controls, where do the experts think the field is heading? 🎧 Listen to the full conversation: https://lnkd.in/eqNkdbyY